巣状分節性糸球体硬化症（FSGS）の世界市場（～2026年）

• 英文タイトル：Global Focal Segmental Glomerulosclerosis (FSGS) Market Insights and Forecast to 2026

• レポートコード：MRC2-11QY06364 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,170,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は巣状分節性糸球体硬化症（FSGS）のグローバル市場について調査・分析したレポートです。種類別（原発性巣状分節性糸球体硬化症、続発性巣状分節性糸球体硬化症）市場規模、用途別（病院、外来外科センター、専門クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別巣状分節性糸球体硬化症（FSGS）の競争状況、市場シェア ・世界の巣状分節性糸球体硬化症（FSGS）市場：種類別市場規模 2015年-2020年（原発性巣状分節性糸球体硬化症、続発性巣状分節性糸球体硬化症） ・世界の巣状分節性糸球体硬化症（FSGS）市場：種類別市場規模予測 2021年-2026年（原発性巣状分節性糸球体硬化症、続発性巣状分節性糸球体硬化症） ・世界の巣状分節性糸球体硬化症（FSGS）市場：用途別市場規模 2015年-2020年（病院、外来外科センター、専門クリニック） ・世界の巣状分節性糸球体硬化症（FSGS）市場：用途別市場規模予測 2021年-2026年（病院、外来外科センター、専門クリニック） ・北米の巣状分節性糸球体硬化症（FSGS）市場分析：米国、カナダ ・ヨーロッパの巣状分節性糸球体硬化症（FSGS）市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの巣状分節性糸球体硬化症（FSGS）市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の巣状分節性糸球体硬化症（FSGS）市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの巣状分節性糸球体硬化症（FSGS）市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Variant Pharmaceuticals、ChemoCentryx、Retrophin、Novartis、Pfizer、AstraZeneca、Sanofi、GlaxoSmithKline、Teva Pharmaceutical ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Focal Segmental Glomerulosclerosis (FSGS) is a cause of nephrotic syndrome in children and adolescents, as well as a leading cause of kidney failure in adults.

Market Analysis and Insights: Global Focal Segmental Glomerulosclerosis (FSGS) Market
The global Focal Segmental Glomerulosclerosis (FSGS) market size is projected to reach US$ 7214.4 million by 2026, from US$ 6889.2 million in 2020, at a CAGR of 4.4%% during 2021-2026.

Global Focal Segmental Glomerulosclerosis (FSGS) Scope and Market Size
Focal Segmental Glomerulosclerosis (FSGS) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Focal Segmental Glomerulosclerosis (FSGS) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Focal Segmental Glomerulosclerosis (FSGS) market is segmented into
Primary Focal Segmental Glomerulosclerosis
Secondary Focal Segmental Glomerulosclerosis

Segment by Application, the Focal Segmental Glomerulosclerosis (FSGS) market is segmented into
Hospitals
Ambulatory Surgical Centers
Specialty Clinics

Regional and Country-level Analysis
The Focal Segmental Glomerulosclerosis (FSGS) market is analysed and market size information is provided by regions (countries).
The key regions covered in the Focal Segmental Glomerulosclerosis (FSGS) market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Focal Segmental Glomerulosclerosis (FSGS) Market Share Analysis
Focal Segmental Glomerulosclerosis (FSGS) market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Focal Segmental Glomerulosclerosis (FSGS) business, the date to enter into the Focal Segmental Glomerulosclerosis (FSGS) market, Focal Segmental Glomerulosclerosis (FSGS) product introduction, recent developments, etc.

The major vendors covered:
Variant Pharmaceuticals
ChemoCentryx
Retrophin
Novartis
Pfizer
AstraZeneca
Sanofi
GlaxoSmithKline
Teva Pharmaceutical

レポート目次

---

1 Study Coverage
1.1 Focal Segmental Glomerulosclerosis (FSGS) Product Introduction
1.2 Market Segments
1.3 Key Focal Segmental Glomerulosclerosis (FSGS) Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Focal Segmental Glomerulosclerosis (FSGS) Market Size Growth Rate by Type
1.4.2 Primary Focal Segmental Glomerulosclerosis
1.4.3 Secondary Focal Segmental Glomerulosclerosis
1.5 Market by Application
1.5.1 Global Focal Segmental Glomerulosclerosis (FSGS) Market Size Growth Rate by Application
1.5.2 Hospitals
1.5.3 Ambulatory Surgical Centers
1.5.4 Specialty Clinics
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Market Size, Estimates and Forecasts
2.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue 2015-2026
2.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Sales 2015-2026
2.2 Global Focal Segmental Glomerulosclerosis (FSGS), Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Focal Segmental Glomerulosclerosis (FSGS) Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Focal Segmental Glomerulosclerosis (FSGS) Competitor Landscape by Players
3.1 Focal Segmental Glomerulosclerosis (FSGS) Sales by Manufacturers
3.1.1 Focal Segmental Glomerulosclerosis (FSGS) Sales by Manufacturers (2015-2020)
3.1.2 Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Manufacturers (2015-2020)
3.2 Focal Segmental Glomerulosclerosis (FSGS) Revenue by Manufacturers
3.2.1 Focal Segmental Glomerulosclerosis (FSGS) Revenue by Manufacturers (2015-2020)
3.2.2 Focal Segmental Glomerulosclerosis (FSGS) Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Focal Segmental Glomerulosclerosis (FSGS) Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Focal Segmental Glomerulosclerosis (FSGS) Revenue in 2019
3.2.5 Global Focal Segmental Glomerulosclerosis (FSGS) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Focal Segmental Glomerulosclerosis (FSGS) Price by Manufacturers
3.4 Focal Segmental Glomerulosclerosis (FSGS) Manufacturing Base Distribution, Product Types
3.4.1 Focal Segmental Glomerulosclerosis (FSGS) Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Focal Segmental Glomerulosclerosis (FSGS) Product Type
3.4.3 Date of International Manufacturers Enter into Focal Segmental Glomerulosclerosis (FSGS) Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Focal Segmental Glomerulosclerosis (FSGS) Market Size by Type (2015-2020)
4.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Sales by Type (2015-2020)
4.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue by Type (2015-2020)
4.1.3 Focal Segmental Glomerulosclerosis (FSGS) Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Focal Segmental Glomerulosclerosis (FSGS) Market Size Forecast by Type (2021-2026)
4.2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Sales Forecast by Type (2021-2026)
4.2.2 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Forecast by Type (2021-2026)
4.2.3 Focal Segmental Glomerulosclerosis (FSGS) Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Focal Segmental Glomerulosclerosis (FSGS) Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Focal Segmental Glomerulosclerosis (FSGS) Market Size by Application (2015-2020)
5.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Sales by Application (2015-2020)
5.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue by Application (2015-2020)
5.1.3 Focal Segmental Glomerulosclerosis (FSGS) Price by Application (2015-2020)
5.2 Focal Segmental Glomerulosclerosis (FSGS) Market Size Forecast by Application (2021-2026)
5.2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Sales Forecast by Application (2021-2026)
5.2.2 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Forecast by Application (2021-2026)
5.2.3 Global Focal Segmental Glomerulosclerosis (FSGS) Price Forecast by Application (2021-2026)

6 North America
6.1 North America Focal Segmental Glomerulosclerosis (FSGS) by Country
6.1.1 North America Focal Segmental Glomerulosclerosis (FSGS) Sales by Country
6.1.2 North America Focal Segmental Glomerulosclerosis (FSGS) Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Focal Segmental Glomerulosclerosis (FSGS) Market Facts & Figures by Type
6.3 North America Focal Segmental Glomerulosclerosis (FSGS) Market Facts & Figures by Application

7 Europe
7.1 Europe Focal Segmental Glomerulosclerosis (FSGS) by Country
7.1.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Sales by Country
7.1.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Market Facts & Figures by Type
7.3 Europe Focal Segmental Glomerulosclerosis (FSGS) Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) by Region
8.1.1 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Sales by Region
8.1.2 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Market Facts & Figures by Type
8.3 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Market Facts & Figures by Application

9 Latin America
9.1 Latin America Focal Segmental Glomerulosclerosis (FSGS) by Country
9.1.1 Latin America Focal Segmental Glomerulosclerosis (FSGS) Sales by Country
9.1.2 Latin America Focal Segmental Glomerulosclerosis (FSGS) Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Focal Segmental Glomerulosclerosis (FSGS) Market Facts & Figures by Type
9.3 Central & South America Focal Segmental Glomerulosclerosis (FSGS) Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) by Country
10.1.1 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Sales by Country
10.1.2 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Market Facts & Figures by Type
10.3 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Market Facts & Figures by Application

11 Company Profiles
11.1 Variant Pharmaceuticals
11.1.1 Variant Pharmaceuticals Corporation Information
11.1.2 Variant Pharmaceuticals Description and Business Overview
11.1.3 Variant Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Variant Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Products Offered
11.1.5 Variant Pharmaceuticals Related Developments
11.2 ChemoCentryx
11.2.1 ChemoCentryx Corporation Information
11.2.2 ChemoCentryx Description and Business Overview
11.2.3 ChemoCentryx Sales, Revenue and Gross Margin (2015-2020)
11.2.4 ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) Products Offered
11.2.5 ChemoCentryx Related Developments
11.3 Retrophin
11.3.1 Retrophin Corporation Information
11.3.2 Retrophin Description and Business Overview
11.3.3 Retrophin Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Retrophin Focal Segmental Glomerulosclerosis (FSGS) Products Offered
11.3.5 Retrophin Related Developments
11.4 Novartis
11.4.1 Novartis Corporation Information
11.4.2 Novartis Description and Business Overview
11.4.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Novartis Focal Segmental Glomerulosclerosis (FSGS) Products Offered
11.4.5 Novartis Related Developments
11.5 Pfizer
11.5.1 Pfizer Corporation Information
11.5.2 Pfizer Description and Business Overview
11.5.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Pfizer Focal Segmental Glomerulosclerosis (FSGS) Products Offered
11.5.5 Pfizer Related Developments
11.6 AstraZeneca
11.6.1 AstraZeneca Corporation Information
11.6.2 AstraZeneca Description and Business Overview
11.6.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.6.4 AstraZeneca Focal Segmental Glomerulosclerosis (FSGS) Products Offered
11.6.5 AstraZeneca Related Developments
11.7 Sanofi
11.7.1 Sanofi Corporation Information
11.7.2 Sanofi Description and Business Overview
11.7.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Sanofi Focal Segmental Glomerulosclerosis (FSGS) Products Offered
11.7.5 Sanofi Related Developments
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Corporation Information
11.8.2 GlaxoSmithKline Description and Business Overview
11.8.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.8.4 GlaxoSmithKline Focal Segmental Glomerulosclerosis (FSGS) Products Offered
11.8.5 GlaxoSmithKline Related Developments
11.9 Teva Pharmaceutical
11.9.1 Teva Pharmaceutical Corporation Information
11.9.2 Teva Pharmaceutical Description and Business Overview
11.9.3 Teva Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Teva Pharmaceutical Focal Segmental Glomerulosclerosis (FSGS) Products Offered
11.9.5 Teva Pharmaceutical Related Developments
11.1 Variant Pharmaceuticals
11.1.1 Variant Pharmaceuticals Corporation Information
11.1.2 Variant Pharmaceuticals Description and Business Overview
11.1.3 Variant Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Variant Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Products Offered
11.1.5 Variant Pharmaceuticals Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Focal Segmental Glomerulosclerosis (FSGS) Market Estimates and Projections by Region
12.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Sales Forecast by Regions 2021-2026
12.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Forecast by Regions 2021-2026
12.2 North America Focal Segmental Glomerulosclerosis (FSGS) Market Size Forecast (2021-2026)
12.2.1 North America: Focal Segmental Glomerulosclerosis (FSGS) Sales Forecast (2021-2026)
12.2.2 North America: Focal Segmental Glomerulosclerosis (FSGS) Revenue Forecast (2021-2026)
12.2.3 North America: Focal Segmental Glomerulosclerosis (FSGS) Market Size Forecast by Country (2021-2026)
12.3 Europe Focal Segmental Glomerulosclerosis (FSGS) Market Size Forecast (2021-2026)
12.3.1 Europe: Focal Segmental Glomerulosclerosis (FSGS) Sales Forecast (2021-2026)
12.3.2 Europe: Focal Segmental Glomerulosclerosis (FSGS) Revenue Forecast (2021-2026)
12.3.3 Europe: Focal Segmental Glomerulosclerosis (FSGS) Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Focal Segmental Glomerulosclerosis (FSGS) Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Focal Segmental Glomerulosclerosis (FSGS) Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Focal Segmental Glomerulosclerosis (FSGS) Market Size Forecast by Region (2021-2026)
12.5 Latin America Focal Segmental Glomerulosclerosis (FSGS) Market Size Forecast (2021-2026)
12.5.1 Latin America: Focal Segmental Glomerulosclerosis (FSGS) Sales Forecast (2021-2026)
12.5.2 Latin America: Focal Segmental Glomerulosclerosis (FSGS) Revenue Forecast (2021-2026)
12.5.3 Latin America: Focal Segmental Glomerulosclerosis (FSGS) Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Focal Segmental Glomerulosclerosis (FSGS) Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Focal Segmental Glomerulosclerosis (FSGS) Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Focal Segmental Glomerulosclerosis (FSGS) Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Focal Segmental Glomerulosclerosis (FSGS) Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Focal Segmental Glomerulosclerosis (FSGS) Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Focal Segmental Glomerulosclerosis (FSGS) Market Segments
Table 2. Ranking of Global Top Focal Segmental Glomerulosclerosis (FSGS) Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Focal Segmental Glomerulosclerosis (FSGS) Market Size Growth Rate by Type 2020-2026 (Kg) & (US$ Million)
Table 4. Major Manufacturers of Primary Focal Segmental Glomerulosclerosis
Table 5. Major Manufacturers of Secondary Focal Segmental Glomerulosclerosis
Table 6. Global Focal Segmental Glomerulosclerosis (FSGS) Market Size Growth Rate by Application 2020-2026 (Kg)
Table 7. Global Focal Segmental Glomerulosclerosis (FSGS) Market Size by Region (Kg) & (US$ Million): 2020 VS 2026
Table 8. Global Focal Segmental Glomerulosclerosis (FSGS) Sales by Regions 2015-2020 (Kg)
Table 9. Global Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Regions (2015-2020)
Table 10. Global Focal Segmental Glomerulosclerosis (FSGS) Revenue by Regions 2015-2020 (US$ Million)
Table 11. Global Focal Segmental Glomerulosclerosis (FSGS) Sales by Manufacturers (2015-2020) (Kg)
Table 12. Global Focal Segmental Glomerulosclerosis (FSGS) Sales Share by Manufacturers (2015-2020)
Table 13. Global Focal Segmental Glomerulosclerosis (FSGS) Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 14. Global Focal Segmental Glomerulosclerosis (FSGS) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Focal Segmental Glomerulosclerosis (FSGS) as of 2019)
Table 15. Focal Segmental Glomerulosclerosis (FSGS) Revenue by Manufacturers (2015-2020) (US$ Million)
Table 16. Focal Segmental Glomerulosclerosis (FSGS) Revenue Share by Manufacturers (2015-2020)
Table 17. Key Manufacturers Focal Segmental Glomerulosclerosis (FSGS) Price (2015-2020) (USD/Kg)
Table 18. Focal Segmental Glomerulosclerosis (FSGS) Manufacturers Manufacturing Base Distribution and Headquarters
Table 19. Manufacturers Focal Segmental Glomerulosclerosis (FSGS) Product Type
Table 20. Date of International Manufacturers Enter into Focal Segmental Glomerulosclerosis (FSGS) Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Global Focal Segmental Glomerulosclerosis (FSGS) Sales by Type (2015-2020) (Kg)
Table 23. Global Focal Segmental Glomerulosclerosis (FSGS) Sales Share by Type (2015-2020)
Table 24. Global Focal Segmental Glomerulosclerosis (FSGS) Revenue by Type (2015-2020) (US$ Million)
Table 25. Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Share by Type (2015-2020)
Table 26. Focal Segmental Glomerulosclerosis (FSGS) Average Selling Price (ASP) by Type 2015-2020 (USD/Kg)
Table 27. Global Focal Segmental Glomerulosclerosis (FSGS) Sales by Application (2015-2020) (Kg)
Table 28. Global Focal Segmental Glomerulosclerosis (FSGS) Sales Share by Application (2015-2020)
Table 29. North America Focal Segmental Glomerulosclerosis (FSGS) Sales by Country (2015-2020) (Kg)
Table 30. North America Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Country (2015-2020)
Table 31. North America Focal Segmental Glomerulosclerosis (FSGS) Revenue by Country (2015-2020) (US$ Million)
Table 32. North America Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Country (2015-2020)
Table 33. North America Focal Segmental Glomerulosclerosis (FSGS) Sales by Type (2015-2020) (Kg)
Table 34. North America Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Type (2015-2020)
Table 35. North America Focal Segmental Glomerulosclerosis (FSGS) Sales by Application (2015-2020) (Kg)
Table 36. North America Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Application (2015-2020)
Table 37. Europe Focal Segmental Glomerulosclerosis (FSGS) Sales by Country (2015-2020) (Kg)
Table 38. Europe Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Country (2015-2020)
Table 39. Europe Focal Segmental Glomerulosclerosis (FSGS) Revenue by Country (2015-2020) (US$ Million)
Table 40. Europe Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Country (2015-2020)
Table 41. Europe Focal Segmental Glomerulosclerosis (FSGS) Sales by Type (2015-2020) (Kg)
Table 42. Europe Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Type (2015-2020)
Table 43. Europe Focal Segmental Glomerulosclerosis (FSGS) Sales by Application (2015-2020) (Kg)
Table 44. Europe Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Application (2015-2020)
Table 45. Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Sales by Region (2015-2020) (Kg)
Table 46. Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Region (2015-2020)
Table 47. Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Revenue by Region (2015-2020) (US$ Million)
Table 48. Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Region (2015-2020)
Table 49. Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Sales by Type (2015-2020) (Kg)
Table 50. Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Type (2015-2020)
Table 51. Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Sales by Application (2015-2020) (Kg)
Table 52. Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Application (2015-2020)
Table 53. Latin America Focal Segmental Glomerulosclerosis (FSGS) Sales by Country (2015-2020) (Kg)
Table 54. Latin America Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Country (2015-2020)
Table 55. Latin Americaa Focal Segmental Glomerulosclerosis (FSGS) Revenue by Country (2015-2020) (US$ Million)
Table 56. Latin America Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Country (2015-2020)
Table 57. Latin America Focal Segmental Glomerulosclerosis (FSGS) Sales by Type (2015-2020) (Kg)
Table 58. Latin America Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Type (2015-2020)
Table 59. Latin America Focal Segmental Glomerulosclerosis (FSGS) Sales by Application (2015-2020) (Kg)
Table 60. Latin America Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Application (2015-2020)
Table 61. Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Sales by Country (2015-2020) (Kg)
Table 62. Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Country (2015-2020)
Table 63. Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Revenue by Country (2015-2020) (US$ Million)
Table 64. Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Country (2015-2020)
Table 65. Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Sales by Type (2015-2020) (Kg)
Table 66. Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Type (2015-2020)
Table 67. Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Sales by Application (2015-2020) (Kg)
Table 68. Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Application (2015-2020)
Table 69. Variant Pharmaceuticals Corporation Information
Table 70. Variant Pharmaceuticals Description and Major Businesses
Table 71. Variant Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Production (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 72. Variant Pharmaceuticals Product
Table 73. Variant Pharmaceuticals Recent Development
Table 74. ChemoCentryx Corporation Information
Table 75. ChemoCentryx Description and Major Businesses
Table 76. ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) Production (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 77. ChemoCentryx Product
Table 78. ChemoCentryx Recent Development
Table 79. Retrophin Corporation Information
Table 80. Retrophin Description and Major Businesses
Table 81. Retrophin Focal Segmental Glomerulosclerosis (FSGS) Production (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 82. Retrophin Product
Table 83. Retrophin Recent Development
Table 84. Novartis Corporation Information
Table 85. Novartis Description and Major Businesses
Table 86. Novartis Focal Segmental Glomerulosclerosis (FSGS) Production (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 87. Novartis Product
Table 88. Novartis Recent Development
Table 89. Pfizer Corporation Information
Table 90. Pfizer Description and Major Businesses
Table 91. Pfizer Focal Segmental Glomerulosclerosis (FSGS) Production (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 92. Pfizer Product
Table 93. Pfizer Recent Development
Table 94. AstraZeneca Corporation Information
Table 95. AstraZeneca Description and Major Businesses
Table 96. AstraZeneca Focal Segmental Glomerulosclerosis (FSGS) Production (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 97. AstraZeneca Product
Table 98. AstraZeneca Recent Development
Table 99. Sanofi Corporation Information
Table 100. Sanofi Description and Major Businesses
Table 101. Sanofi Focal Segmental Glomerulosclerosis (FSGS) Production (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 102. Sanofi Product
Table 103. Sanofi Recent Development
Table 104. GlaxoSmithKline Corporation Information
Table 105. GlaxoSmithKline Description and Major Businesses
Table 106. GlaxoSmithKline Focal Segmental Glomerulosclerosis (FSGS) Production (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 107. GlaxoSmithKline Product
Table 108. GlaxoSmithKline Recent Development
Table 109. Teva Pharmaceutical Corporation Information
Table 110. Teva Pharmaceutical Description and Major Businesses
Table 111. Teva Pharmaceutical Focal Segmental Glomerulosclerosis (FSGS) Production (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 112. Teva Pharmaceutical Product
Table 113. Teva Pharmaceutical Recent Development
Table 114. Global Focal Segmental Glomerulosclerosis (FSGS) Sales Forecast by Regions (2021-2026) (Kg)
Table 115. Global Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share Forecast by Regions (2021-2026)
Table 116. Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 117. Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share Forecast by Regions (2021-2026)
Table 118. North America: Focal Segmental Glomerulosclerosis (FSGS) Sales Forecast by Country (2021-2026) (Kg)
Table 119. North America: Focal Segmental Glomerulosclerosis (FSGS) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 120. Europe: Focal Segmental Glomerulosclerosis (FSGS) Sales Forecast by Country (2021-2026) (Kg)
Table 121. Europe: Focal Segmental Glomerulosclerosis (FSGS) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 122. Asia Pacific: Focal Segmental Glomerulosclerosis (FSGS) Sales Forecast by Region (2021-2026) (Kg)
Table 123. Asia Pacific: Focal Segmental Glomerulosclerosis (FSGS) Revenue Forecast by Region (2021-2026) (US$ Million)
Table 124. Latin America: Focal Segmental Glomerulosclerosis (FSGS) Sales Forecast by Country (2021-2026) (Kg)
Table 125. Latin America: Focal Segmental Glomerulosclerosis (FSGS) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 126. Middle East and Africa: Focal Segmental Glomerulosclerosis (FSGS) Sales Forecast by Country (2021-2026) (Kg)
Table 127. Middle East and Africa: Focal Segmental Glomerulosclerosis (FSGS) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 128. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 129. Key Challenges
Table 130. Market Risks
Table 131. Main Points Interviewed from Key Focal Segmental Glomerulosclerosis (FSGS) Players
Table 132. Focal Segmental Glomerulosclerosis (FSGS) Customers List
Table 133. Focal Segmental Glomerulosclerosis (FSGS) Distributors List
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
List of Figures
Figure 1. Focal Segmental Glomerulosclerosis (FSGS) Product Picture
Figure 2. Global Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Type in 2020 & 2026
Figure 3. Primary Focal Segmental Glomerulosclerosis Product Picture
Figure 4. Secondary Focal Segmental Glomerulosclerosis Product Picture
Figure 5. Global Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Application in 2020 & 2026
Figure 6. Hospitals
Figure 7. Ambulatory Surgical Centers
Figure 8. Specialty Clinics
Figure 9. Focal Segmental Glomerulosclerosis (FSGS) Report Years Considered
Figure 10. Global Focal Segmental Glomerulosclerosis (FSGS) Market Size 2015-2026 (US$ Million)
Figure 11. Global Focal Segmental Glomerulosclerosis (FSGS) Sales 2015-2026 (Kg)
Figure 12. Global Focal Segmental Glomerulosclerosis (FSGS) Market Size Market Share by Region: 2020 Versus 2026
Figure 13. Global Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Region (2015-2020)
Figure 14. Global Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Region in 2019
Figure 15. Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Region (2015-2020)
Figure 16. Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Region in 2019
Figure 17. Global Focal Segmental Glomerulosclerosis (FSGS) Sales Share by Manufacturer in 2019
Figure 18. The Top 10 and 5 Players Market Share by Focal Segmental Glomerulosclerosis (FSGS) Revenue in 2019
Figure 19. Focal Segmental Glomerulosclerosis (FSGS) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 20. Global Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Type (2015-2020)
Figure 21. Global Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Type in 2019
Figure 22. Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Type (2015-2020)
Figure 23. Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Type in 2019
Figure 24. Global Focal Segmental Glomerulosclerosis (FSGS) Market Share by Price Range (2015-2020)
Figure 25. Global Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Application (2015-2020)
Figure 26. Global Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Application in 2019
Figure 27. Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Application (2015-2020)
Figure 28. Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Application in 2019
Figure 29. North America Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate 2015-2020 (Kg)
Figure 30. North America Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 31. North America Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Country in 2019
Figure 32. North America Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Country in 2019
Figure 33. U.S. Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 34. U.S. Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 35. Canada Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 36. Canada Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. North America Focal Segmental Glomerulosclerosis (FSGS) Market Share by Type in 2019
Figure 38. North America Focal Segmental Glomerulosclerosis (FSGS) Market Share by Application in 2019
Figure 39. Europe Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate 2015-2020 (Kg)
Figure 40. Europe Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 41. Europe Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Country in 2019
Figure 42. Europe Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Country in 2019
Figure 43. Germany Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 44. Germany Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 45. France Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 46. France Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. U.K. Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 48. U.K. Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. Italy Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 50. Italy Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Russia Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 52. Russia Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Europe Focal Segmental Glomerulosclerosis (FSGS) Market Share by Type in 2019
Figure 54. Europe Focal Segmental Glomerulosclerosis (FSGS) Market Share by Application in 2019
Figure 55. Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate 2015-2020 (Kg)
Figure 56. Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 57. Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Region in 2019
Figure 58. Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Region in 2019
Figure 59. China Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 60. China Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Japan Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 62. Japan Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. South Korea Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 64. South Korea Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. India Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 66. India Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. Australia Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 68. Australia Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Taiwan Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 70. Taiwan Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Indonesia Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 72. Indonesia Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Thailand Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 74. Thailand Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Malaysia Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 76. Malaysia Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Philippines Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 78. Philippines Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Vietnam Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 80. Vietnam Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Market Share by Type in 2019
Figure 82. Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Market Share by Application in 2019
Figure 83. Latin America Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate 2015-2020 (Kg)
Figure 84. Latin America Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 85. Latin America Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Country in 2019
Figure 86. Latin America Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Country in 2019
Figure 87. Mexico Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 88. Mexico Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 89. Brazil Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 90. Brazil Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Argentina Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 92. Argentina Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Latin America Focal Segmental Glomerulosclerosis (FSGS) Market Share by Type in 2019
Figure 94. Latin America Focal Segmental Glomerulosclerosis (FSGS) Market Share by Application in 2019
Figure 95. Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate 2015-2020 (Kg)
Figure 96. Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 97. Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Country in 2019
Figure 98. Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Revenue Market Share by Country in 2019
Figure 99. Turkey Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 100. Turkey Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 101. Saudi Arabia Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 102. Saudi Arabia Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. U.A.E Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate (2015-2020) (Kg)
Figure 104. U.A.E Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Market Share by Type in 2019
Figure 106. Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Market Share by Application in 2019
Figure 107. North America Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate Forecast (2021-2026) (Kg)
Figure 108. North America Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 109. Europe Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate Forecast (2021-2026) (Kg)
Figure 110. Europe Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate Forecast (2021-2026) (Kg)
Figure 112. Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Latin America Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate Forecast (2021-2026) (Kg)
Figure 114. Latin America Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Sales Growth Rate Forecast (2021-2026) (Kg)
Figure 116. Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Porter's Five Forces Analysis
Figure 118. Channels of Distribution
Figure 119. Distributors Profiles
Figure 120. Bottom-up and Top-down Approaches for This Report
Figure 121. Data Triangulation
Figure 122. Key Executives Interviewed

---